Rajaram

“Yeah, but actually, if you look at the fourth quarter tends to be a little bit more of a management of how the sales have gone, because on a full year basis, if you look at it, the growth will be closer to 20% for the EU region.”

“And if I may just add, I think the important thing is that unlike human generics, where the pricing drops very drastically to almost 10-15% of the innovator's price, I mean, what happens in animal health generics is that the pricing drop to the generics is far slower.”